Aptamers - basic research, drug development, and clinical applications

被引:211
作者
Proske, D
Blank, M
Buhmann, R
Resch, A
机构
[1] NascaCell IP GmbH, D-3181377 Munich, Germany
[2] GSF Munich, Natl Res Ctr Environm & Hlth, Munich, Germany
关键词
D O I
10.1007/s00253-005-0193-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Since its discovery in the early 1990s, aptamer technology has progressed tremendously. Automated selection procedures now allow rapid identification of DNA and RNA sequences that can target a broad range of extra-and intracellular proteins with nanomolar affinities and high specificities. The unique binding properties of nucleic acids, which are amenable to various modifications, make aptamers perfectly suitable for different areas of biotechnology. Moreover, the approval of an aptamer for vascular endothelial growth factor by the US Food and Drug Administration highlights the potential of aptamers for therapeutic applications. This review summarizes recent developments and demonstrates that aptamers are valuable tools for diagnostics, purification processes, target validation, drug discovery, and even therapeutic approaches.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 69 条
[1]  
*ANT, 2005, PROM PHAS 1 DAT AN A
[2]   Aptasensor development: Elucidation of critical parameters for optimal aptamer performance [J].
Baldrich, E ;
Restrepo, A ;
O'Sullivan, CK .
ANALYTICAL CHEMISTRY, 2004, 76 (23) :7053-7063
[3]   Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen [J].
Blank, M ;
Weinschenk, T ;
Priemer, M ;
Schluesener, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16464-16468
[4]   Cytoplasmic RNA modulators of an inside-out signal-transduction cascade [J].
Blind, M ;
Kolanus, W ;
Famulok, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3606-3610
[5]  
Blind M., 2002, SCREENING, V6, P35
[6]   Photoaptamer arrays applied to multiplexed proteomic analysis [J].
Bock, C ;
Coleman, M ;
Collins, B ;
Davis, J ;
Foulds, G ;
Gold, L ;
Greef, C ;
Heil, J ;
Heilig, JS ;
Hicke, B ;
Hurst, MN ;
Husar, GM ;
Miller, D ;
Ostroff, R ;
Petach, H ;
Schneider, D ;
Vant-Hull, B ;
Waugh, S ;
Weiss, A ;
Wilcox, SK ;
Zichi, D .
PROTEOMICS, 2004, 4 (03) :609-618
[7]   The use of aptamers in large arrays for molecular diagnostics [J].
Brody, EN ;
Willis, MC ;
Smith, JD ;
Jayasena, S ;
Zichi, D ;
Gold, L .
MOLECULAR DIAGNOSIS, 1999, 4 (04) :381-388
[8]   Aptamers as tools for target prioritization and lead identification [J].
Burgstaller, P ;
Girod, A ;
Blind, M .
DRUG DISCOVERY TODAY, 2002, 7 (24) :1221-1228
[9]   Direct in vitro selection of a 2′-O-methyl aptamer to VEGF [J].
Burmeister, PE ;
Lewis, SD ;
Silva, RF ;
Preiss, JR ;
Horwitz, LR ;
Pendergrast, PS ;
McCauley, TG ;
Kurz, JC ;
Epstein, DM ;
Wilson, C ;
Keefe, AD .
CHEMISTRY & BIOLOGY, 2005, 12 (01) :25-33
[10]   Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 [J].
Chen, CHB ;
Chernis, GA ;
Hoang, VQ ;
Landgraf, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) :9226-9231